stockrow
Saturday 31 October 2026
Export BMY’s income statement to Excel — free account
Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
62.55
1.16
+1.89%
Follow BMY
Alert me
Bristol Myers Squibb Company (BMY) revenue by segment, product and region
Where the money comes from and where it goes
| United States | 33,279 | 69.05% |
|---|---|---|
| International | 13,828 | 28.69% |
| Other | 1,087 | 2.26% |
| Gross margin | 71.08% | |
| Operating margin | 19.36% | |
| Pre-tax margin | 19.36% |
Revenue by product or service $m
| Line | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|
| Eliquis | 7,929 30.33% | 6,438 28.54% | 4,872 23.45% | 3,343 17.21% | 1,860 11.23% | 774 4.87% | 146 0.89% | — | — | — |
| Opdivo | 7,204 27.55% | 6,735 29.85% | 4,948 23.82% | 3,774 19.43% | 942 5.69% | 6 0.04% | — | — | — | — |
| Orencia | 2,977 11.39% | 2,710 12.01% | 2,479 11.93% | 2,265 11.66% | 1,885 11.38% | 1,652 10.40% | 1,444 8.81% | 917 4.32% | 733 3.76% | 602 3.20% |
| Mature Products And All Other | 2,287 8.75% | 2,357 10.45% | 3,945 18.99% | 2,271 11.69% | 3,818 23.06% | 3,400 21.41% | 4,878 29.77% | 2,950 13.89% | 3,170 16.27% | 3,645 19.38% |
| Sprycel | 2,110 8.07% | 2,000 8.86% | 2,005 9.65% | 1,824 9.39% | 1,620 9.78% | 1,493 9.40% | 1,280 7.81% | 803 3.78% | 576 2.96% | 421 2.24% |
| Yervoy | 1,489 5.70% | 1,330 5.90% | 1,244 5.99% | 1,053 5.42% | 1,126 6.80% | 1,308 8.24% | 960 5.86% | 360 1.69% | — | — |
| Revlimid | 1,299 4.97% | 0 0.00% | 0 0.00% | — | — | — | — | — | — | — |
| Empliciti | 357 1.37% | 247 1.09% | 231 1.11% | 150 0.77% | 3 0.02% | — | — | — | — | — |
| Pomalyst/Imnovid | 322 1.23% | 0 0.00% | 0 0.00% | — | — | — | — | — | — | — |
| Abraxane | 166 0.63% | 0 0.00% | 0 0.00% | — | — | — | — | — | — | — |
| Inrebic | 5 0.02% | 0 0.00% | 0 0.00% | — | — | — | — | — | — | — |
| Abecma | 0 0.00% | — | — | — | — | — | — | — | — | — |
| Breyanzi | 0 0.00% | — | — | — | — | — | — | — | — | — |
| Onureg | 0 0.00% | 0 0.00% | — | — | — | — | — | — | — | — |
| Reblozyl | 0 0.00% | 0 0.00% | — | — | — | — | — | — | — | — |
| Zeposia | 0 0.00% | 0 0.00% | — | — | — | — | — | — | — | — |
| Baraclude | — | 744 3.30% | 1,052 5.06% | 1,192 6.14% | 1,312 7.92% | 1,441 9.07% | 1,527 9.32% | 1,196 5.63% | 931 4.78% | 734 3.90% |
| Vidaza | — | 0 0.00% | 0 0.00% | — | — | — | — | — | — | — |
| Hepatitis C Portfolio | — | — | — | 1,578 8.12% | 1,603 9.68% | 256 1.61% | — | — | — | — |
| Sustiva Franchise | — | — | — | 1,065 5.48% | 1,252 7.56% | 1,444 9.09% | 1,614 9.85% | 1,485 6.99% | 1,368 7.02% | 1,277 6.79% |
| Reyataz | — | — | — | 912 4.69% | 1,139 6.88% | 1,362 8.58% | 1,551 9.47% | 1,569 7.39% | 1,479 7.59% | 1,401 7.45% |
| Abilify | — | — | — | — | — | 2,020 12.72% | 2,289 13.97% | 2,758 12.98% | 2,565 13.16% | 2,592 13.78% |
| Erbitux | — | — | — | — | — | 723 4.55% | 696 4.25% | 691 3.25% | 662 3.40% | 683 3.63% |
| Plavix | — | — | — | — | — | — | — | 7,087 33.36% | 6,666 34.21% | 6,146 32.68% |
| Avapro Avalide | — | — | — | — | — | — | — | 952 4.48% | 1,176 6.04% | 1,283 6.82% |
| Onglyza Kombiglyze | — | — | — | — | — | — | — | 473 2.23% | 158 0.81% | 24 0.13% |
| Nulojix | — | — | — | — | — | — | — | 3 0.01% | — | — |
| Revenue | 26,145 | 22,561 | 20,776 | 19,427 | 16,560 | 15,879 | 16,385 | 21,244 | 19,484 | 18,808 |
Revenue by region $m
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 33,279 69.05% | 34,105 70.61% | 31,210 69.35% | 31,500 68.24% | 29,214 62.98% | 26,577 62.51% | 15,342 58.68% | 12,586 55.79% | 11,358 54.67% | 10,720 55.18% | 8,188 49.44% | 7,716 48.59% | 8,318 50.77% | 10,384 58.93% | 14,039 66.08% | 12,800 65.69% | 11,867 63.10% |
| International | 13,828 28.69% | 13,199 27.33% | 13,097 29.10% | 13,825 29.95% | 16,319 35.18% | 15,310 36.01% | 6,266 23.97% | 5,658 25.08% | 4,988 24.01% | 4,215 21.70% | 3,491 21.08% | 3,592 22.62% | 3,930 23.99% | 3,706 21.03% | 3,879 18.26% | 3,672 18.85% | 3,625 19.27% |
| Other | 1,087 2.26% | 996 2.06% | 699 1.55% | 834 1.81% | 852 1.84% | 631 1.48% | 524 2.00% | 584 2.59% | 553 2.66% | 528 2.72% | 739 4.46% | 1,112 7.00% | 842 5.14% | 327 1.86% | 89 0.42% | 112 0.57% | 198 1.05% |
| Rest Of World | — | — | — | — | — | — | 4,013 15.35% | 3,733 16.55% | 3,877 18.66% | 3,964 20.40% | 4,142 25.01% | 3,459 21.78% | 3,295 20.11% | 3,204 18.18% | 3,237 15.24% | 2,900 14.88% | — |
| Japan, Asia Pacific, and Canada | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1,522 8.09% |
| Latin America, Middle East And Africa | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 843 4.48% |
| Emerging Markets | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 753 4.00% |
| Revenue | 48,194 | 48,300 | 45,006 | 46,159 | 46,385 | 42,518 | 26,145 | 22,561 | 20,776 | 19,427 | 16,560 | 15,879 | 16,385 | 17,621 | 21,244 | 19,484 | 18,808 |